With a new pen and needle attached, turn the dose selector to the flow check symbol
Results develop progressively and may require a series of treatments
Current evidence suggests future protocols may include three stages: Initiation Phase 14 mg weekly 812 week metabolic adaptation Active Weight-Loss Phase 612 mg weekly 612 months Maintenance Phase 36 mg weekly If ongoing trials confirm early findings, retatrutide could become one of the most effective pharmacologic interventions for obesity ever developed
Starting at 0.25 mg weekly and titrated up to 2.4 mg, it provides: Potent glycemic control Clinically significant weight loss Metabolic and cardiovascular benefits It represents a well-established and effective therapeutic option for patients seeking long-term metabolic health improvement.
It is designed for adults battling obesity or those who are overweight with accompanying health issues
Wang J-L, Yang Q, Hajnal A, Rogers AM